Faeth Therapeutics, Inc.
Ownership
Ownership Structure
Who owns Faeth Therapeutics, Inc. (FTH)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 71.6% of the shares are freely tradable; institutional investors hold 25.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.82 | 2,020,103 | +5,747.1 | 06/30/2026 |
| venBio Select Advisor LLC | 5.59 | 1,444,039 | +0.0 | 06/30/2026 |
| Baker Bros Advisors LP | 4.98 | 1,286,411 | +0.0 | 06/30/2026 |
| Balyasny Asset Management LLC | 4.03 | 1,042,198 | +6,331.3 | 06/30/2026 |
| Cormorant Asset Management, LLC | 3.98 | 1,028,242 | +235.8 | 06/30/2026 |
| Vivo Capital, LLC | 2.79 | 722,020 | +0.0 | 06/30/2026 |
| RA Capital Management, LLC | 2.79 | 722,020 | +0.0 | 06/30/2026 |
| Fairmount Funds Management LLC | 2.79 | 722,020 | +0.0 | 06/30/2026 |
| Logos Global Management LP | 2.79 | 722,020 | +2,306.7 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Polar Capital Biotech S Inc | 4.72 | 1,220,631 | +0.0 | 09/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Parikh Anand Kiran | President and CEO | 100,000 | 1,000,000 $ | Oct 30, 2026 | indirect |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Oct 30, 2026 | Parikh Anand Kiran | President and CEO | Other | 100,000 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: November 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.